FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer ‘Tranq’ Or ”Zombie Drug’
The FDA issued an “import alert” about the animal tranquilizer xylazine, also called “tranq,” “tranq dope,” and “zombie drug.” The…
After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytruda Regime Study In Lung Cancer Patients
Merck & Co Inc’s (NYSE:MRK) Phase 3 KEYNOTE-671 trial investigating Keytruda met one of its dual primary endpoints, event-free survival…
Johnson & Johnson-Backed Antiviral Candidate Effectively Prevents Influenza Infection
Cidara Therapeutics Inc (NASDAQ: CDTX) announced efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain.
IVERIC bio’s Geographic Atrophy Candidate Shows Significant Reduction In Disease Progression
IVERIC bio Inc (NASDAQ:ISEE) announced an exploratory time-to-event analysis from the avacincaptad pegol (ACP) GATHER clinical trial program evaluating the reduction…
FDA AdComm Gives Thumbs Up To Pfizer’s RSV Vaccine Candidate For Elderly People
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted in favor of Pfizer Inc’s (NYSE:PFE) available data is adequate to…
FDA Rejects Cytokinetics’ Heart Failure Treatment Candidate
The FDA issued a Complete Response Letter to Cytokinetics Incorporated’s (NASDAQ:CYTK) omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for…
FDA Approves Regeneron-Sanofi’s Sarilumab As First Biologic For Stiffness, Pain In Muscles
The FDA approved Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The approval…
Novavax Ushers New CEO On Uncertainty Concerns, Says It Needs To Work On Competitive COVID-19 Product
COVID-19 vaccine maker Novavax Inc (NASDAQ: NVAX) shares plunged after it
Why Reata Pharma Shares Are Skyrocketing Today
The FDA approved Reata Pharmaceuticals Inc’s (NASDAQ:RETA) Skyclarys (omaveloxolone) for Friedreich’s ataxia in adults and adolescents aged 16 and older. With…
Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race
Guggenheim Partners initiated coverage on Structure Therapeutics Inc (NASDAQ:GPCR) with a Buy rating and a price target of $50 based on the multi-billion-dollar…